Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

QT

Quince Therapeutics, Inc.

$32.7

-0.78 (-2.33%)

C 47Pipeline Score Overvalued Biotech · Clinical
Market Cap
33.26 M
EPS
-90.92
P/E Ratio
-
Value Trade
1.03 M
0.27 %
Week
84.87 %
1 Month
37.5 %
3 Month
18.53 %
6 Month
-99.7 %
5 Year
-99.85 %
All Time
Cash Data

  • Cash Position

    -

  • Monthly Burn

    -

  • Runway

    -

Overview
Volume
6.83 K
52 Week Range
15.10 - 909.98
% held by Insiders
3.66 %
% held by Institutions
33.89 %
Enterprise Value
-82.42 M
Total Shares
1.02 M
Short %
5.78 %
Float Shares
15.27 M
Company Description
HQ: 611 GATEWAY BLVD., SUITE 273, ...
Employees:38
https://www.quincetx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
NDA Submission example
NDA
—

Subscribe to access the data.

Cell Therapies
Rare Diseases
NDA
—

Subscribe to access the data.

Cell Therapies
Rare Diseases
NDA
—

Subscribe to access the data.

Cell Therapies
Rare Diseases
Unlock Upcoming Catalyst data

Catalyst Timeline

Dated clinical, regulatory & corporate events for Quince Therapeutics, Inc.

110Total events
8Upcoming
28Tier-1 (high impact)
2019 – 2028Coverage

Upcoming catalysts 2

TBD
T2Trial Initiation
Subscribe to view catalyst details
LAM-001
TBD
T2Trial Initiation
Subscribe to view catalyst details
LAM-001

Event history 2

TBD
▲Trial InitiationLAM-001Trial
Subscribe to view catalyst details
TBD
▲Enrollment CompleteLAM-001Trial
Subscribe to view catalyst details
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2026-03-31
encapsulated dexamethasone sodium phosphate (eDSP)
Phase 3 topline data readout
Phase 3
—
–
–
–
2026-03-31
encapsulated dexamethasone sodium phosphate (eDSP)
Phase 3 topline data readout
Phase 3
—
–
–
–
2026-03-31
encapsulated dexamethasone sodium phosphate (eDSP)
Phase 3 topline data readout
Phase 3
—
–
–
–
Unlock Historical Catalyst data
Drug Pipeline Intelligence
C47
Pipeline Score
$18M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.5x
rNPV / MCap
Top 74%
Micro Cap
(rank 244 of 933)
Percentile Rank
Quince Therapeutics, Inc. carries a moderate pipeline score (47/100), with $725M risk-adjusted pipeline value, led by EryDex Low dose DSP in Nervous System Disease (Phase 3), across $157B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
EryDex Low dose DSP
Small molecule		Nervous System DiseasePhase 3NCT0277080754% $441M COMPLETED 176 - -May 13, 2021 -May 10, 2024
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
LAM-001
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Phase 2a
2026-05-18

6MWD increase: 67.4 meters; PVR reduction: 33.9%

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

Read More
LAM-001
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Phase 2a
2026-05-18

6MWD increase: 67.4 meters; PVR reduction: 33.9%

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

Read More
LAM-001
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Phase 2a
2026-05-18

6MWD increase: 67.4 meters; PVR reduction: 33.9%

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in QNCX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
QNCX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-10-16 0.00 0 - - - - - -
2026-10-16 0.00 0 - - - - - -
2026-10-16 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-QNCX
Aug 14, 2026
QNCXGeneral
▲ +5%on this news

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Quince Therapeutics reported its second quarter 2026 financial results, highlighting the acquisition of Orphai Therapeutics and the addition of LAM-001 to its pipeline. The company anticipates Phase 2b data for LAM-001 in pulmonary hypertension associated with interstitial lung disease by early 2028. Despite a net loss of $75.5 million, Quince maintains a strong cash position of $116 million, expected to support operations through 2028.

Read more →
-QNCX
Jun 30, 2026
QNCXPhases

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

Quince Therapeutics has established a Scientific Advisory Board (SAB) comprising experts in pulmonary medicine to advance the development of LAM-001, an inhaled formulation of rapamycin. The SAB will focus on multiple pulmonary indications, including pulmonary hypertension associated with interstitial lung disease. The company is optimistic about LAM-001's potential benefits based on positive Phase 2a trial results.

Read more →
-QNCX
May 18, 2026
QNCXPhases
▼ -13.5%on this news

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

Quince Therapeutics announced positive results from its Phase 2a study of LAM-001, an inhaled mTOR inhibitor, in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study demonstrated significant improvements in lung function, including a 67.4-meter increase in six-minute walk distance (6MWD) and a 33.9% reduction in pulmonary vascular resistance (PVR). A Phase 2b trial is set to begin in mid-2026, with topline data expected in early 2028.

Read more →
-QNCX
May 18, 2026
QNCXGeneral
▼ -13.5%on this news

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

Quince Therapeutics has acquired Orphai Therapeutics, gaining access to LAM-001, an inhaled rapamycin formulation targeting rare pulmonary diseases. The acquisition is supported by a $187 million private placement, with $115 million upfront. Quince plans to initiate Phase 2b trials for pulmonary hypertension associated with interstitial lung disease and bronchiolitis obliterans syndrome, with data expected in 2027 and 2028.

Read more →
-QNCX
May 18, 2026
QNCXPhases
▼ -13.5%on this news

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD Data from Phase 2a study of LAM-001 on top of standard of care in

Quince Therapeutics, Inc. announced promising results from its Phase 2a study of LAM-001, an inhaled formulation aimed at treating patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study showed significant improvements across various clinical endpoints, including a notable increase in the six-minute walk distance (6MWD) and reductions in pulmonary vascular resistance (PVR). The data supports LAM-001's potential as an effective therapy in this area of unmet medical need. The company plans to advance LAM-001 into a Phase 2b trial later this year.

Read more →
-QNCX
Mar 30, 2026
QNCXGeneral
▲ +15.6%on this news

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics has settled approximately $16.4 million of debt. This financial move may impact the company's balance sheet positively, but further details on the implications for operations or future plans are not provided.

Read more →
-QNCX
Jan 30, 2026
QNCXPhases
▼ -37.1%on this news

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Quince Therapeutics announced that its pivotal Phase 3 NEAT trial for eDSP in Ataxia-Telangiectasia did not meet its primary or key secondary endpoints, leading the company to halt further development of the drug. Despite the lack of efficacy, eDSP was well tolerated with no major safety issues reported. The company aims to preserve cash and explore other options.

Read more →
-QNCX
Jan 29, 2026
QNCXPhases

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Quince Therapeutics presented safety data from a long-term study of encapsulated dexamethasone sodium phosphate (eDSP) for children with Ataxia-Telangiectasia (A-T) at the British Paediatric Neurology Association Annual Meeting. The analysis focused on the safety profile of eDSP, which has been administered for at least two years. The company is advancing a Phase 3 clinical trial for eDSP and expects to report topline results in early 2026.

Read more →
-QNCX
Jan 29, 2026
QNCXPhases

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia Primary and key secondary endpoint did not achieve statistical significance eDSP was ge

Quince Therapeutics announced the topline results from its pivotal Phase 3 NEAT clinical trial of eDSP for Ataxia-Telangiectasia. The trial did not achieve statistical significance for its primary and key secondary endpoints, leading the company to cease development of the drug. Although eDSP was well tolerated, the failure to meet expected outcomes raises concerns about its viability as a treatment option.

Read more →
-QNCX
Nov 12, 2025
QNCXPhases

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results Pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline result

Quince Therapeutics recently provided an update detailing its financial results for Q3 2025 and the status of its pivotal Phase 3 NEAT clinical trial for eDSP, aimed at treating Ataxia-Telangiectasia. The trial remains on track, with topline results anticipated in the first quarter of 2026. Positive insights include a favorable safety analysis from an independent monitoring board and full participation in the open label extension study. However, the company reported a net loss, indicating ongoing financial pressures as they prepare for future regulatory submissions.

Read more →
-QNCX
Aug 11, 2025
QNCXPhases

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for t

Quince Therapeutics announced a significant milestone with the completion of enrollment in its Phase 3 NEAT clinical trial for eDSP, aimed at treating Ataxia-Telangiectasia (A-T). The company also reported a cash position of approximately $35 million following a recent financing round, expected to support operations through key upcoming trial results. Additionally, Quince formed a partnership with Option Care Health to facilitate the U.S. launch of eDSP. Despite these advancements, the company reported a net loss of $16.1 million for the second quarter of 2025.

Read more →
-QNCX
Jul 16, 2025
QNCXPhases

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics has successfully completed enrollment in the pivotal Phase 3 NEAT clinical trial for its lead product, eDSP, aimed at treating Ataxia-Telangiectasia (A-T). This milestone is significant for the company as it moves closer to potentially delivering a first treatment for this rare disease. The CEO expressed confidence in the trial's design and oversight, with topline results expected in early 2026, followed by an NDA submission later that year. A-T is a severe neurodegenerative disorder with no currently approved therapies.

Read more →
-QNCX
May 13, 2025
QNCXPhases

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results Plan to potentially conclude enrollment early for Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T) to align topline

Quince Therapeutics provided a business update and reported its first quarter 2025 financial results, revealing plans for the Phase 3 NEAT clinical trial for Ataxia-Telangiectasia. The company may conclude enrollment early by June 2025 to better align topline results with its existing cash runway. While enrollment has been slower than expected due to various challenges, the company remains hopeful for positive trial results and subsequent regulatory submissions in 2026. Quince reported a net loss of $15 million for this quarter, prompting a focus on strategic funding solutions to maintain operations.

Read more →
-QNCX
Mar 24, 2025
QNCXPhases

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results Phase 3 NEAT clinical trial exceeds 50% enrollment with new study site activations expected to accelerate screenings and randomi

Quince Therapeutics announced a significant update regarding its Phase 3 NEAT clinical trial, reporting over 50% enrollment and expecting new site activations to further boost participant screenings. The company's fiscal year 2024 financial results showed a cash position of $40.8 million, projected to sustain operations into 2026. Despite reporting a net loss for the year, Quince is progressing with plans for additional studies and has established a dedicated Scientific Advisory Board. The anticipated topline results from the NEAT trial are expected in the fourth quarter of 2025.

Read more →
-QNCX
Nov 13, 2024
QNCXPhases

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enro

Quince Therapeutics has reported a positive update regarding its Phase 3 NEAT clinical trial, noting that 32 patients have been enrolled to date. The company expects to maintain enrollment momentum and aims to complete it by Q2 2025, with topline results anticipated in Q4 2025. Additionally, Quince provided its third quarter financial results, revealing a net loss of $5.5 million, but it maintains a strong cash position sufficient to fund operations into 2026.

Read more →
-QNCX
Aug 13, 2024
QNCXPhases
▼ -16.5%on this news

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results Strong cash position expected to provide sufficient operating runway into 2026 Phase 3 topline results expected in the fourth

Quince Therapeutics has reported its financial results for Q2 2024, highlighting a strong cash position that is expected to support operations through 2026. The company is advancing its pivotal Phase 3 clinical trial for EryDex in Ataxia-Telangiectasia, with the first patient enrolled and a total of seven participants recruited. Additionally, Quince anticipates topline results in Q4 2025, paving the way for potential NDA and MAA submissions in 2026. Despite a significant net loss reported for the quarter, the company's ongoing developments and strategic initiatives showcase a promising outlook.

Read more →
-QNCX
Jul 24, 2023
QNCXGeneral

Quince Therapeutics to Acquire EryDel

Quince Therapeutics plans to acquire EryDel, aiming to enhance its capabilities in developing EryDex, a treatment for Ataxia-Telangiectasia. The acquisition has been unanimously approved by both companies' boards and involves a stock-for-stock exchange, as well as potential milestone cash payments. EryDex has shown promise in prior trials with a favorable safety profile and plans for a Phase 3 trial starting in mid-2024, contingent on successful outcomes. This acquisition may position Quince for future growth, given the significant market potential of EryDex in addressing an unmet medical need.

Read more →
-QNCX
Apr 5, 2023
QNCXGeneral

Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

Quince Therapeutics has implemented a limited duration stockholder rights plan to safeguard against unsolicited acquisition proposals and control threats. The plan will be effective for one year, expiring on April 5, 2024, and includes special provisions that activate if an entity acquires a certain percentage of shares without Board approval. This strategy aims to ensure that stockholders realize long-term value while allowing the Board to evaluate strategic alternatives. Additionally, Quince is seeking a financial advisor to assist in these evaluations.

Read more →
-QNCX
Aug 1, 2022
QNCXGeneral

Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name Strategic focus centered on advancing innovative precision therapeutics for debilitating and rare diseases Highly different

Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name Strategic focus centered on advancing innovative precision therapeutics for debilitating and rare diseases Highly differentiated bone-targeting drug platform and lead precision bone growth mole

Read more →
-QNCX
May 10, 2022
QNCXGeneral

Cortexyme Announces Agreement to Acquire Novosteo Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novost

Cortexyme Announces Agreement to Acquire Novosteo Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen Smith as

Read more →
-QNCX
Feb 15, 2021
QNCXPhases

Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer s Disease Double-blind phase of GAIN Trial to continue as planned, with top-line data expected Q4 2021 Open-Label Extension of atu

Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer s Disease Double-blind phase of GAIN Trial to continue as planned, with top-line data expected Open-Label Extension of atuzaginstat to stop dosing and enrollment SOUTH SAN FRANCISCO, Cali

Read more →
-QNCX
Jan 26, 2021
QNCXGeneral

Investor Contact: Chris Lowe Cortexyme, Inc. Chief Financial Officer clowe@cortexyme.com Media Contact: Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 Cortexyme Announces Pipeline Update and Anticipat

Cortexyme Announces Pipeline Update and Anticipated 2021 Milestones Based upon successful completion of the GAIN Trial s interim analysis, pipeline expansion announced for 2021 Atuzaginstat to be studied in the PEAK trial, a new Phase 2 study for Parkinson s disease COR588, a

Read more →
-QNCX
May 12, 2020
QNCXGeneral

Investor Contact: Chris Lowe Cortexyme, Inc. Chief Financial Officer clowe@cortexyme.com Media Contact: Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 Cortexyme Announces First Quarter 2020 Financial

Investor Contact: Chris Lowe Cortexyme, Inc. Chief Financial Officer clowe@cortexyme.com Media Contact: Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update Inter

Read more →
-QNCX
Mar 17, 2020
QNCXGeneral

Investor Contact: Chris Lowe Cortexyme, Inc. Chief Financial Officer clowe@cortexyme.com Media Contact: Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 Cortexyme Announces Fourth Quarter and Full Year

Investor Contact: Chris Lowe Cortexyme, Inc. Chief Financial Officer clowe@cortexyme.com Media Contact: Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Busine

Read more →
-QNCX
Feb 5, 2020
QNCXGeneral

Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 Cortexyme Announces $125 Million Private Placement

Media Contact: Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 Cortexyme Announces $125 Million Private Placement SOUTH SAN FRANCISCO, Calif. February 5, 2020 Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneeri

Read more →
-QNCX
May 8, 2019
QNCXGeneral

Chris Lowe Chief Financial Officer Cortexyme, Inc. clowe@cortexyme.com Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 CORTEXYME, INC. ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING South San F

Contacts: Chris Lowe Chief Financial Officer Cortexyme, Inc. clowe@cortexyme.com Hal Mackins For Cortexyme, Inc. hal@torchcomllc.com (415) 994-0040 CORTEXYME, INC. ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING South San Francisco, Calif. May 8,

Read more →
Competitive Position
How QNCX ranks across every disease it competes in
Competitive Position is a premium feature
See how QNCX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial